The structure and features of the course of chronic kidney disease in patients with coronary heart disease and comorbid diseases

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Aim. To investigate the prevalence, structure, and features of the course of chronic kidney disease (CKD) in patients with coronary heart disease (CHD) associated with comorbid diseases.

Methods. The observation group consisted of 257 patients of the Interregional Clinical Diagnostic Center (Kazan) with coronary heart disease (2014–2018): 183 males and 74 females, aged from 38 to 95 years (mean age 61.8±0.6). Observation program: clinical examination; serum creatinine and lipid profiles, the albumin/creatinine ratio in a single portion of urine, morning urine osmolality, glomerular filtration rate estimated by the CKD-EPI; renal scintigraphy, ultrasonography of the kidneys, renal Doppler ultrasound and angiography. Chronic kidney disease was diagnosed if one of the criteria was met: the glomerular filtration rate <60 ml/min/1.73 m2 or the ratio of albumin to creatinine in urine (ACR) >30 mg/g. Statistical analysis was performed by using the methods of variational statistics: determination of the arithmetic mean (M), standard error of the mean (m) and difference significance according to the Student's test (t).

Results. Examination of patients revealed the following comorbid diseases and syndromes: hypertension (90.7%), hyper- and dyslipidemia (96.5%), overweight/obesity (74.3%), diabetes mellitus (17.9%), chronic heart failure stages I–IIa according to Strazhesko–Vasilenko classification (100%). 164 (63.8%) patients were first time diagnosed with chronic kidney disease: hypertensive nephropathy — in 66.4%, ischemic renal disease — in 21.9%, diabetic nephropathy — in 2.4%, a combination of diabetic and hypertensive nephropathy — in 9.3%. 51.2% of patients had stage 2 of chronic kidney disease, 42.1% — stage 3, 6.7% — stage 4 or 5. A feature of chronic kidney disease is its latent course (absence of complaints and clinical manifestations) and, as a consequence, unidentified diagnosis at the prehospital stage, which is generally characteristic of secondary nephropathies in cardiovascular diseases and these comorbid conditions.

Conclusion. Chronic kidney disease was first diagnosed in 63.8% of patients with coronary heart disease with 1 to 5 comorbid diseases; a feature of chronic kidney disease is its secondary nature, the course of the disease is hidden by underlying and/or comorbid disease and, as a result, its late diagnosis.

Full Text

Restricted Access

About the authors

O N Sigitova

Kazan State Medical University

Author for correspondence.
Russian Federation, Kazan, Russia

A R Bogdanova

Kazan (Volga Region) Federal University

Russian Federation, Kazan, Russia

T Yu Kim

Kazan State Medical University

Russian Federation, Kazan, Russia


  1. Karpov Yu.A., Sorokin E.V. Stabil'naya ishemicheskaya bolezn' serdtsa: strategiya i taktika lecheniya. (Stable coronary artery disease: treatment strategy and tactics.) 2nd ed. M.: MIA. 2012; 271 р. (In Russ.)
  2. Karpov Yu.A., Kukharchuk V.V., Lyakishev A.A., Lupanov V.P., Panchenko E.P., Komarov A.L., Ezhov M.V., Shiryaev A.A., Samko A.N., Soboleva G.N., Sorokin E.V. Diagnosis and treatment of chronic ischemic heart disease (clinical guidelines). Kardiologicheskiy vestnik. 2015; 10 (3): 3–33. (In Russ.)
  3. Kardiologiya. Natsional'noe rukovodstvo. (Cardiology. A national guide.) Ed. by E.V. Shlyakhto. 2nd ed. M.: GEOTAR-Media. 2015; 800 р. (In Russ.)
  4. Moiseev V.S., Mukhin N.A., Smirnov A.V., Kobalava Zh.D., Bobkova I.N., Villeval'de S.V., Efremovtseva M.A., Kozlovskaya L.V., Shvetsov M.Yu., Shestakova M.V., Arutyunov G.P., Boytsov S.A., Galyavich A.S., Grinshteyn Yu.I., Dobronravov V.A., Drapkina O.M., Ermolenko V.M., Karpov Yu.A., Kayukov I.G., Kotovskaya Yu.V., Kukharchuk V.V., Martynov A.I., Morozova T.E., Oga­nov R.G., Podzolkov V.I., Rozhinskaya L.Ya., Tereshchenko S.N., Fomin V.V., Khirmanov V.N., Chazova I.E., Shamkhalova M.Sh., Shilov E.M., Shlyakhto E.V., Shutov A.M. Cardiovascular risk and chronic kidney disease: cardio-­nephroprotection strategies. Russian Journal of Cardio­logy. 2014; (8): 7–37. (In Russ.) doi: 10.15829/1560-4071-2014-8-7-37.
  5. Masoudi F.A., Rathore S.S., Wang Y., Havranek E.P., Curtis J.P., Foody J.M., Krumholz H.M. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004; 110 (6): 724–731. doi: 10.1161/01.cir.0000138934.28340.ed.
  6. Ruelope L.M., Salvetti A., Jamerson K., Hansson L., Warnold I., Wedel H., Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive parti­cipants of the hypertension optimal treatment (HOJ) study. J. Am. Soc. Nephrol. 2001; 12 (2): 218–225. doi: 10.1681/ASN.V122218.
  7. Haroun N.K., Jaar B.G., Hoffman S.C., Comstock G.W., Klag M.J., Coresh J. Risk factors for ­chronic kidney disease: A prospective study of 23,534 men and women in Washington Country, Maryland. J. Am. Soc. Nephrol. 2003; 14 (11): 2934–2941. doi: 10.1097/01.asn.0000095249.99803.85.
  8. Tomilina N.A., Andrusev A.M., Peregudova N.G., Shinkarev M.B. Renal replacement the­rapy for end stage renal disease in Russian Federation, 2010–2015. Russian national renal replacement therapy registry report of russian public organization of nephrologists “Russian dialysis so­ciety”. Part 1. Nefrologiya i dializ. 2017; 19 (Suppl. 4): 1–95. (In Russ.) doi: 10.28996/1680-4422-2017-4suppl-1-95.
  9. Smirnov A.V., Dobronravov V.A., Kisina A.A., Rumyantsev A.Sh., Kayukov I.G. Diabeticheskaja nefropatija: proekt klinicheskih rekomendacij NONR. (Diabetic nephropathy: Draft clinical guidelines of the SSRN.) M. 2013.Рекомендации-диабетическая-нефропатия.pdf (access date: 24.04.2021). (In Russ.)
  10. Farag Y.M., Gaballa M.R. Diabesity: an overview of a rising epidemic. Nephrol. Dial. Transplant. 2011; 26: 28–35. doi: 10.1093/ndt/gfq576.
  11. Wu Y., Liu Z., Xiang Z., Zeng C., Chen Z., Ma X., Li L. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal ­biopsy samples. Endocrinology. 2006; 147: 44–50. doi: 10.1210/en.2005-0641.
  12. Chagnac A., Weinstein T., Herman M., Hirsh J., Gafter U., Ori Y. The effects of weight loss on renal function in patients with severe obesity. Am. Soc. Nephrol. 2014; 146: 1480–1486. doi: 10.1097/01.asn.0000068462.38661.89.
  13. Sethi S., Zand L., Nasr S.H., Glassock R.J., Fervenza F.C. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin. Kidney J. 2014; 7: 531–537. doi: 10.1093/ckj/sfu100.
  14. Tsuboi N., Koike K., Hirano K., Utsunomiya Y., Kawamura T., Hosoya T. Clinical features and long-term renal outcomes of Japanese patients with obesity-rela­ted glomerulopathy. Clin. Exp. Nephrol. 2013; 17: 379–385. doi: 10.1007/s10157-012-0719-y.
  15. Chen H.M., Chen Y., Zhang Y.D., Zhang P.P., Chen H.P., Wang Q.W., Li L.S., Liu Z.H. Evaluation of metabolic risk marker in obesity-related glomerulopathy. J. Ren. Nutr. 2011; 21 (4): 309–315. doi: 10.1053/j.jrn.­2010.06.019.
  16. Diagnostika, lechenie, profilaktika ozhirenija i associirovannyh s nim zabolevanij (nacional'nye klinicheskie rekomendacii). (Diagnostics, treatment, prevention of obesity and associated diseases (national clinical guidelines).) St. Petersburg. 2017. (access date: 24.04.2021). (In Russ.)
  17. Efremova E.V., Shutov A.M., Podusov A.S., Markevich M.P. Biomarkers of myocardial and renal dysfunction in chro­nic heart failure. Nefrologiya i dializ. 2020; 22 (2): 181–188. (In Russ.) doi: 10.28996/2618-9801-2020-2-181-188.
  18. Shilov E.M., Smirnov A.V., Kozlovskaja N.L. Nefrologija. Klinicheskie rekomendacii. (Nephrology. Clinical guidelines.) M.: GEOTAR-Media. 2016; 816 р. (In Russ.)

Supplementary files

Supplementary Files
1. Рис. 1. Липидный профиль у пациентов с ишемической болезнью сердца (ммоль/л); **р <0,01; ***р <0,001; ХС — холестерин; ЛПВП — липопротеиды высокой плотности; ЛПНП — липопротеиды низкой плотности; ЛПОНП — липопротеиды очень низкой плотности; ТГ — триглицериды

Download (12KB)

© 2021 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies